Labcorp Posts 7% Revenue Growth in 2025, Expands Specialty Testing Portfolio — Labcorp Holdings Inc.

Event summary

Labcorp reported 7.2% year-over-year revenue growth to $13.95 billion in 2025, with Q4 revenue at $3.52 billion.
Adjusted EPS grew 12.9% year-over-year to $16.44, with Q4 adjusted EPS at $4.07.
The company completed four acquisitions in Q4, expanding its health system and regional laboratory partnerships.
Labcorp launched over 130 new specialty tests in 2025, including an FDA-cleared Alzheimer's disease blood test.
Announced a strategic investment to build a 500,000 square foot Central Laboratory facility in Indiana.

The big picture

Labcorp's strong 2025 performance underscores its strategic focus on expanding its diagnostics and central laboratory businesses. The company's investments in specialty testing and facility expansion reflect broader industry trends toward personalized medicine and technological innovation in healthcare diagnostics. With a robust pipeline of new tests and strategic acquisitions, Labcorp is positioning itself to capitalize on growing demand for advanced diagnostic services.

What we're watching

Execution Risk: The pace at which Labcorp can integrate its recent acquisitions and expand its specialty testing portfolio will be critical to sustaining growth.
Market Dynamics: How the company's strategic investment in a new Central Laboratory facility will position it against competitors in the rapidly evolving diagnostics market.
Regulatory Headwinds: Whether Labcorp can maintain its leadership in specialty testing amid potential regulatory changes and healthcare policy shifts.